Biotek-snakken — Oktober 2023
-
Sedana Medical AB’s Interim report January-September 2023
All-time-high Q3 sales and further steps towards ex-US profitability
-
Calliditas Asien-partner får Nefecon-godkännande i Macao
Läkemedelsbolaget Calliditas asiatiska partner Everest Medicines meddelar att Nefecon fått grönt ljus i Macao för behandling av njursjukdomen IgAN.
-
Biotech Stocks Facing FDA Decision In November 2023 https://www.proinvestor.com/investornyt/1070743/biotech-stocks-facing-fda-decision-in-november-2023
-
Exitnu - Jeg syntes virkelig Calliditas ser interessant ud nu. Jeg har selv øget noget de sidste par dage. Usikkerheden er ved at være reduceret betydlig. Dagens børsklima/høje renter holder biotek i et jerngreb. Selv selskaber med færdigudviklet produkter eller produkter på vej til markede bliver holdt nede. Når stemningen vender kan der virkelig være gevinster at hente fra dagens kurser.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind